Prognostic factors for refractory pheochromocytoma and paraganglioma after 131I-metaiodobenzylguanidine therapy-Reference-Cited by-同舟云学术

Prognostic factors for refractory pheochromocytoma and paraganglioma after 131I-metaiodobenzylguanidine therapy

Published:2021-10-13 Issue:1 Volume:36 Page:61-69
ISSN:0914-7187
Container-title:Annals of Nuclear Medicine
language:en
Short-container-title:Ann Nucl Med

Author:

Hiromasa Tomo^ORCID,Wakabayashi Hiroshi,Kayano Daiki,Inaki Anri,Watanabe Satoru,Mori Hiroshi,Akatani Norihito,Yamase Takafumi,Kunita Yuji,Saito Shintaro,Kinuya Seigo

Funder

Fujifilm Corporation

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12149-021-01685-6.pdf

Reference31 articles.

1. Hescot S, Leboulleux S, Amar L, Vezzosi D, Borget I, Bournaud-Salinas C, et al. One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2013;98:4006–12.

2. Hamidi O, Young WF Jr, Gruber L, Smestad J, Yan Q, Ponce OJ, et al. Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: a systematic review and meta-analysis. Clin Endocrinol (Oxf). 2017;87:440–50.

3. Jimenez C, Rohren E, Habra MA, Rich T, Jimenez P, Ayala-Ramirez M, et al. Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr Oncol Rep. 2013;15:356–71.

4. Goffredo P, Sosa JA, Roman SA. Malignant pheochromocytoma and paraganglioma: a population level analysis of long-term survival over two decades. J Surg Oncol. 2013;107:659–64.

5. Hamidi O, Young WF Jr, Iniguez-Ariza NM, Kittah NE, Gruber L, Bancos C, et al. Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. J Clin Endocrinol Metab. 2017;102:3296–305.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive Factors of Early 18F-Fluorodeoxyglucose-Positron Emission Tomography Response to [131I] Metaiodobenzylguanidine Treatment for Unresectable or Metastatic Pheochromocytomas and Paragangliomas;Neuroendocrinology;2023-09-19

2. Recent Advances in Radiopharmaceutical Theranostics of Pheochromocytoma and Paraganglioma;Seminars in Nuclear Medicine;2023-07

3. Alpha-particle Therapy of Endocrine Tumors: Current State and Future Directions;Interdisciplinary Cancer Research;2022